^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)

    i
    Other names: MAP3K5, Mitogen-Activated Protein Kinase Kinase Kinase 5, MAPKKK5, ASK1, MEKK5, Apoptosis Signal-Regulating Kinase 1, MAPK/ERK Kinase Kinase 5, MEK Kinase 5, MEKK 5, ASK-1, Apoptosis Signal Regulating Kinase 1, MAP/ERK Kinase Kinase 5
    Associations

    News

    Trials
    1m
    Thioredoxin-Binding protein 2 and apoptosis Signal-Regulating kinase 1: redox stress sensors and therapeutic targets in hepatocellular carcinoma. (PubMed, Med Oncol)
    Translational challenges include context-dependent effects, biomarker limitations, and delivery specificity. Refining strategies to achieve precise, transient TBP2/ASK1 activation may unlock their tumor-suppressive potential while minimizing inflammatory risk, offering a novel avenue for HCC treatment.
    Review • Journal
    |
    NLRP3 (NLR Family Pyrin Domain Containing 3) • TXNIP (Thioredoxin Interacting Protein) • MAPK8 (Mitogen-activated protein kinase 8) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    3ms
    In Silico and In Vitro Evaluation of Novel Small Molecule Inhibitors Targeting Apoptosis Pathways in Breast Cancer Cells. (PubMed, Asian Pac J Cancer Prev)
    The identified compounds C12 and C18 exhibit potent cytotoxic and pro-apoptotic activity in breast cancer cells, highlighting  their potential as promising novel therapeutic agents. However, further in vivo studies are essential to validate their efficacy and safety profiles.
    Preclinical • Journal
    |
    MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    9ms
    Age-related stress gene expression in neonatal sepsis involves regulatory networks and immune cell infiltration. (PubMed, Sci Rep)
    Immune infiltration analysis revealed profound differences in the composition of immune cells between the normal and NS groups. Our study findings offer valuable information for future research on therapeutic targets and diagnostic markers of NS.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • ETS1 (ETS Proto-Oncogene 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit) • MAPK14 (Mitogen-Activated Protein Kinase 14) • TLR2 (Toll Like Receptor 2) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    |
    PD-L1 expression
    11ms
    The involvement of TRPV1 in the apoptosis of spermatogenic cells in the testis of mice with cryptorchidism. (PubMed, Cell Death Discov)
    Transcriptome sequencing revealed that the expression of apoptosis-related genes (Capn1, Capn2, Bax, Aifm1, Caspase 3, Map3k5, Itpr1 and Fas) was down-regulated in spermatocytes of cryptorchid Trpv1-/- mice. Our results suggest that TRPV1 promotes the apoptosis of spermatocytes in cryptorchid mice by regulating the expression of apoptosis-related genes.
    Preclinical • Journal
    |
    CASP3 (Caspase 3) • TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1) • AIF1 (Allograft Inflammatory Factor 1) • CAPN1 (Calpain 1) • CAPN2 (Calpain 2) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    12ms
    Identification of telomere-related gene subtypes and prognostic signatures in osteosarcoma. (PubMed, Front Pharmacol)
    In conclusion, our study has uncovered the importance of TRGs in defining distinct subtypes of OS with different survival outcomes and immune contexts. The telomere-related signature we developed may serve as a valuable tool for prognosis prediction and could inform future therapeutic strategies targeting the TME in OS.
    Journal
    |
    PPARG (Peroxisome Proliferator Activated Receptor Gamma) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    1year
    A telomere-related signature for predicting prognosis and assessing immune microenvironment in osteosarcoma. (PubMed, Front Pharmacol)
    A telomere-related signature was constructed in osteosarcoma patients, offering predictive values into prognosis, the immune microenvironment, and drug sensitivity. Moreover, MAP7 might serve as a prognostic marker for osteosarcoma patients.
    Journal
    |
    PPARG (Peroxisome Proliferator Activated Receptor Gamma) • MAP7 (Microtubule Associated Protein 7) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    1year
    Exploring MAP3K genes in gastric cancer: biomarkers, tumor microenvironment dynamics, and chemotherapy resistance. (PubMed, Hereditas)
    This comprehensive assessment provides valuable insights into the role of MAP3K genes in GC, offering avenues for further research and therapeutic exploration.
    Journal
    |
    MAP3K10 (Mitogen-Activated Protein Kinase Kinase Kinase 10) • MIR200B (MicroRNA 200b) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • MAP3K14 (Mitogen-Activated Protein Kinase Kinase Kinase 14) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11) • MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    over1year
    CRLF1 bridges AKT and mTORC2 through SIN1 to inhibit pyroptosis and enhance chemo-resistance in ovarian cancer. (PubMed, Cell Death Dis)
    High CRLF1-expressing tumors showed sensitivity to AKT inhibition but tolerance to cisplatin...Thus, CRLF1 critically regulates chemoresistance in ovarian cancer by modulating AKT/SIN1-dependent pyroptosis. Binding-defective CRLF1 variants could be developed as tumor-specific polypeptide drugs to enhance chemotherapy for ovarian cancer.
    Journal
    |
    CASP3 (Caspase 3) • GSDME (Gasdermin E) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    |
    cisplatin
    over1year
    Cetylpyridinium chloride triggers paraptosis to suppress pancreatic tumor growth via the ERN1-MAP3K5-p38 pathway. (PubMed, iScience)
    Subsequently, the endoplasmic reticulum stress to nucleus signaling 1 (ERN1)-mitogen-activated protein kinase kinase kinase 5 (MAP3K5)-p38 mitogen-activated protein kinase (MAPK) signaling pathway was activated, ultimately culminating in the induction of paraptosis. In vivo experiments, including those involving patient-derived xenografts, orthotopic models, and genetically engineered mouse models of PDAC, provided further evidence of CPC's effectiveness in suppressing the growth of pancreatic tumors.
    Journal
    |
    ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    over1year
    Fe3O4-Coated CNTs-Gum Arabic Nano-Hybrid Composites Exhibit Enhanced Anti-Leukemia Potency Against AML Cells via ROS-Mediated Signaling. (PubMed, Int J Nanomedicine)
    We provide an effective Fe3O4 NPs/CNTs nano-hybrid composite that induces apoptosis and has strong anti-leukemic capabilities. This hybrid nanocomposite is promising for in vivo testing and validation.
    Journal
    |
    CD34 (CD34 molecule) • CASP3 (Caspase 3) • FOXO3 (Forkhead box O3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • SIRT1 (Sirtuin 1) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    over1year
    Comprehensive analysis of MAPK genes in the prognosis, immune characteristics, and drug treatment of renal clear cell carcinoma using bioinformatic analysis and Mendelian randomization. (PubMed, Eur J Pharmacol)
    Knockout and overexpression validation experiments in vitro and in vivo found that MAP3K12 acted as a promoter of tumour progression in RCC, suggesting a pivotal role for MAP3K12 in the proliferation, migration, and invasion of RCC cells. Our findings proposed the potential of MAPK-signature genes as biomarkers for prognosis and therapy response, as well as targets for therapeutic drugs in ccRCC.
    Journal • IO biomarker
    |
    MAPK1 (Mitogen-activated protein kinase 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • MAPK8 (Mitogen-activated protein kinase 8) • MAPK9 (Mitogen-Activated Protein Kinase 9) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)
    almost2years
    Identification of methylation driver genes for predicting the prognosis of pancreatic cancer patients based on whole-genome DNA methylation sequencing technology. (PubMed, Heliyon)
    In addition, the malignant phenotypes of PANC-1 cells were decreased after the knockdown of PIK3C2B. Therefore, the prognostic risk prediction model based on the eight key MDGs could accurately predict the prognosis of PCa patients.
    Journal • Epigenetic controller
    |
    PIK3C2B (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta) • FABP4 (Fatty Acid Binding Protein 4) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)